

**Genomic data<sup>1</sup> and tissue specimens at Data Release 7: Incident Breast and Ovarian cancer<sup>2</sup>: Sister Study, overall and 4% random subcohort**

	<b>Total</b>		<b>DNA extracted<sup>3</sup></b>		<b>GWAS<sup>1</sup> Oncoarray</b>		<b>Methylation<sup>1</sup> LINE 1</b>		<b>Methylation<sup>1</sup> 27K</b>		<b>Methylation<sup>1</sup> 450K</b>		<b>Blocks Received<sup>4,5</sup></b>		<b>Slides Only Received<sup>4</sup></b>	
	<b>N</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	<b>N</b>	<b>%</b>	
<b>Sister Study participants (All)</b>	50,884	13,432	26.4	4,912	9.7	1,035	2.0	1,043	2.0	3,073	6.0	2,284	4.5	295	0.6	
Incident Breast Cancer (any type) <sup>6</sup>	3,512	3,024	86.1	2,356	67.1	375	10.7	389	11.1	1,647	46.9	2,186	62.2	283	8.1	
Incident Breast Cancer (DCIS/Invasive) <sup>7</sup>	3,399	2,943	86.6	2,284	67.2	360	10.6	378	11.1	1,647	48.5	2,147	63.2	275	8.1	
Incident Ovarian Cancer <sup>8</sup>	237	198	83.5	149	62.9	8	3.4	7	3.0	20	8.4	76	32.1	9	3.8	
<b>Random subcohort (4% of Sister Study)<sup>9</sup></b>	2,036	1,969	96.7	2,021	99.3	312	15.3	311	15.3	1,336	65.6	102	5.0	14	0.7	
No Breast Cancer (any type) and no Ovarian Cancer <sup>10</sup>	1,879	1,816	96.6	1,865	99.3	273	14.5	274	14.6	1,226	65.2	N/A		N/A		
Incident Breast Cancer (any type) <sup>11</sup>	149	145	97.3	148	99.3	38	25.5	37	24.8	105	70.5	95	63.8	13	8.7	
Incident Ovarian Cancer <sup>11</sup>	8	8	100.0	8	100.0	1	12.5	0	--	5	62.5	4	50.0	0	0.0	
<i>No DCIS/Invasive Breast Cancer and no Ovarian Cancer<sup>10</sup></i>	1,886	1,823	96.7	1,872	99.3	275	14.6	276	14.6	1,227	65.1	N/A		N/A		
<i>Incident DCIS/Invasive Breast Cancer<sup>11</sup></i>	142	138	97.2	141	99.3	36	25.4	35	24.6	104	73.2	92	64.8	13	9.2	
<b>Other<sup>12</sup></b>	1,137	1,079	94.9	558	49.1	382	33.6	376	33.1	192	16.9	N/A		N/A		

<sup>1</sup> Table reflects N of samples sent for assay, not N of samples with usable results. Investigator cutoffs will affect N of usable samples. For study planning, more detailed information is available on request.

<sup>2</sup> Ovarian cancer includes fallopian tube and peritoneal cancers

<sup>3</sup> DNA extracted as of 08/12/2019. >=5 µg of DNA

<sup>4</sup> Includes tissue samples received through 01/24/2020

<sup>5</sup> Includes those where only blocks were received and those where both blocks and slides were received

<sup>6</sup> Includes 1st LCIS/DCIS/Invasive breast cancer. Excludes prevalent breast cancer; breast cancer with unknown timing (incident vs. prevalent); and uncertain breast cancer dx (breast cancer possible but unlikely)

<sup>7</sup> Includes 1st DCIS/Invasive breast cancer. Excludes LCIS, prevalent DCIS/Invasive breast cancer and all DCIS/Invasive breast cancer with unknown timing (incident vs. prevalent) or uncertain dx (breast cancer possible but unlikely)

<sup>8</sup> Excludes prevalent ovarian/fallopian tube/peritoneal cancer; ovarian/fallopian tube/peritoneal cancer timing unknown; and ovarian/fallopian tube/peritoneal cancer uncertain

<sup>9</sup> Included in second sample collection (SCL)

<sup>10</sup> Excludes incident, prevalent, timing unknown and diagnosis uncertain for both breast cancer and ovarian/fallopian tube/peritoneal cancer

<sup>11</sup> Includes n=0 with both incident breast cancer and incident ovarian/fallopian tube/peritoneal cancer. Excludes prevalent, timing unknown and diagnosis uncertain cases

<sup>12</sup> DNA extracted for other projects (not in 4% subcohort, neither an incident breast cancer or ovarian/fallopian tube/peritoneal cancer case)